Scope: Cereal grains are commonly contaminated with Fusarium mycotoxins and their plantderived masked metabolites. The fate of masked mycotoxins in the human gut is poorly understood. Here we assess the metabolism and transport of glucoside metabolites of common trichothecenes (deoxynivalenol, nivalenol, T-2 toxin) and zearalenone compounds (zearalenone, ␣-and ␤-zearalenol) in the human gut in vitro.
Introduction
Fungal disease is a major concern facing agricultural production worldwide and contamination with toxic fungal metabolites, or mycotoxins, was found to affect 84% of agricultural commodity samples globally in a 2015 survey of over 8000 samples [1] . Fusarium fungi pose the main disease pressure in temperate climate regions of the world, causing bleaching of the ears called fusarium head blight in all major small grain cereals. This important fungal genus produces a range of potent Fusarium mycotoxins, which are highly prevalent in cereal-based food and feed raw materials [2] . Two major chemical groups of Fusarium mycotoxins are trichothecenes, sesquiterpene structures with variable side chains, and zearalenone compounds, phenolic resorcyclic acid lactone derivates [3] . Trichothecenes include the most commonly detected mycotoxins deoxynivalenol (DON) and nivalenol (NIV), both type B trichothecenes as well as the type A trichothecenes T-2 and HT-2 toxins (T2 and HT2). Trichothecenes affect nutrient absorption and barrier function in the small intestine and cause immunological disturbances [3, 4] and DON has also been shown to affect neuronal cells [5, 6] . Zearalenone (ZEN) and its hydroxylated derivatives ␣-and ␤-zearalenol (␣-ZEL, ␤-ZEL) are potent estrogenic analogs causing reproductive toxicity [3] .
Due to their well-established toxicity, maximum levels are set for DON and ZEN in food by the European Commission [7] . Recently European Food Safety Authority (EFSA) has published a group health-based guidance value for zearalenone and its related derivatives and conjugates, this is likely to result in a requirement for increased testing and possible changes to permitted limits for these compounds [8] . EFSA is currently reviewing the appropriateness to set group health based guidance values for T-2 and HT-2 toxin and their modified forms and nivalenol and its modified forms as well as assessing the risks for animal and public health related to the presence of deoxynivalenol, metabolites of deoxynivalenol and masked deoxynivalenol in food and feed [9] [10] [11] . While the outcome of these is not yet known it could be expected that the European Commission may make changes to maximum permitted limits in the future.
In response to fungal infection and mycotoxin production the plant uses phase I and II detoxification pathways to prevent any adverse effects of mycotoxin toxicities. Especially phase II conjugation reactions lead to mycotoxin metabolites conjugated to small molecules such as monosaccharides, glutathione, or sulphates [12] , which enable the plant to store mycotoxins in the plant cell vacuole. Sugar conjugates of trichothecenes and zearalenone compounds have been identified in plant materials. The collective term masked mycotoxins has been coined to describe plant-bound mycotoxin metabolites [13, 14] . Most naturally occurring sugarmycotoxin conjugates are covalently bound via ␤-glucosidic bonds (DON3Glc, NIV3Glc, ZEN14Glc) whereas both ␣-and ␤-glucosidic conjugates have been reported for T-2 toxin [15, 16] . Due to the covalent binding of mycotoxins, these compounds have initially been thought to have limited bioavailability hence not contributing to toxicity. Recent studies have shown that DON3Glc is not hydrolyzed by small intestinal enzymes in vitro [17, 18] or in rats [19] and not absorbed through intestinal epithelial monolayers [20] . DON3Glc has also been shown to be less potent than DON in inducing intestinal toxicity ex vivo [21] and cytokine storms and emetic responses in vivo [22, 23] . However, studies using human fecal microbiota and single isolates of human gut microbes have demonstrated microbial hydrolysis of DON3Glc to DON in vitro [17, 18, 24] . Information on other masked Fusarium mycotoxins is scarce with two in vitro studies demonstrating T2Glc [15] and ZEN14Glc [18] to be stable toward digestive juices of the upper GI tract but hydrolyzed by human fecal microbiota [25] .
This study is the first comprehensive comparison of the major glucose conjugates of trichothecenes (DON3Glc, NIV3Glc, T2Glc) and zearalenone compounds (ZEN14Glc, ␣-ZEL14Glc, ␤-ZEL14Glc) to better predict their bioavailability in the human gut. The study assesses stability of these six masked mycotoxins and their respective free parent mycotoxins toward digestive juices of the upper GI tract, their epithelial absorption and their hydrolysis by colonic microbiota in vitro. Furthermore, individual differences in microbial hydrolysis rates between different donors are explored for the masked mycotoxins.
Materials and methods
All mycotoxins used in the present study are summarized in Table 1 . Reference analytical standards of deoxynivalenol, deoxynivalenol-3-␤,D-glucoside, nivalenol, T-2 toxin, HT-2 toxin, and zearalenone were purchased from Romer Labs Ltd, Tulln, Austria. Nivalenol-3-␤,D-glucoside was obtained from Dr. Tomoya Yoshinari, National Institute of Health Sciences, Japan [26] . T-2-3-␣,D-glucoside was obtained from Dr Mark Busman and Dr Susan McCormick, Bacterial Foodborne Pathogens and Mycology Unit, USDA-ARS-NCAUR in the USA. ␣-zearalenol and ␤-zearalenol were purchased from Sigma Aldrich, Gillingham, Dorset, UK. Zearalenone-14-␤,D-glucoside, ␣-zearalenol-14-␤,D-glucoside and ␤-zearalenol-14-␤,D-glucoside were synthesized by Dr. Simon Jones and Dr. Ashlie Butler, Chemistry Department, Sheffield University, UK. All standards were prepared in acetonitrile and kept at 4ЊC (or −18ЊC) during the duration of the study.
Hydrolysis of masked mycotoxins by digestive juices of the upper gut
Hydrolysis of masked mycotoxins (DON3Glc, NIV3Glc, T2Glc, ZEN14Glc, ␣-ZEL14Glc, ␤-ZELGlc) and their respective free mycotoxins (DON, NIV, T-2 toxin, HT-2 toxin, ZEN, ␣-ZEL, and ␤-ZEL) was studied by exposing them to artificial digestive juices mimicking upper GI conditions. All artificial digestive juices (organic and inorganic components of saliva, gastric juice, duodenal juice and bile) were made up as described by Dall'Erta [18] and prepared freshly on the day of the experiment. Each mycotoxin (0.2 nmoles in 2 L acetonitrile) was individually incubated in triplicate in a shaking water bath (37ЊC) with 75 L of artificial saliva (5 min), followed by the addition of 150 L of artificial gastric juice (2 h) and the addition of 25 L NaHCO 3 , 150 L of duodenal juice, and 75 L bile juice (2 h). Reactions were terminated by adding 25 L of acetonitrile, samples were centrifuged (10 000 rpm) and supernatant samples were analyzed by LC-MS/MS. Enzyme-free control incubations were performed simultaneously for all mycotoxins and masked mycotoxins. To account for potential matrix effects each experiment included Membrane integrity of epithelial monolayers was monitored via transepithelial electrical resistance measurements using an EVOM TEER-meter (World Precision Instruments, USA). Cells were then exposed to 2 nmoles/mL of trichothecenes (DON, DON3Glc, NIV, NIV3Glc, T2, T2Glc) or zearalenone compounds (ZEN, ZEN14Glc, ␣-ZEL, ␣-ZEL14Glc, ␤-ZEL, ␤-ZEL14Glc) in serum-free DMEM from the luminal (apical) side for 0, 1, 6, or 24 h and transport to the systemic (basolateral) side was studied. Mycotoxins were measured in cell culture medium using LC-MS/MS. All experiments were performed in triplicate and stability of all mycotoxins in culture medium was assessed in cell-free controls. To account for potential matrix effects each experiment included cellfree culture medium controls (in duplicate) spiked with each mycotoxin or masked mycotoxin individually. Mycotoxins detected in these controls were set as 100% and all other results were calculated as % of control.
Hydrolysis of masked mycotoxins by colonic microbiota
Fecal batch culture experiments were used to study the hydrolysis and metabolism of masked mycotoxins by the human gut microbiota [24] . These experiments utilized freshly collected fecal samples from six donors (2 female, 4 male, age 27-64) handled under anaerobic conditions to mimic colonic conditions. Samples from donors 1-5 were used in experiments with trichothecenes and donors 1-4 and 6 were used in experiments with zearalenone compounds as donor 5 dropped out due to antibiotic use. Three masked trichothecenes (DON3Glc, NIV3Glc, and T2Glc) were studied in the same fresh fecal sample in the same experiment on the same day. Fecal samples were diluted 1/10 under CO 2 with anaerobic M2 culture medium [28] and duplicate aliquots of 1 mL fecal slurry were spiked with 2 nmol of DON3Glc, NIV3Glc, or T2Glc in acetonitrile and incubated anaerobically at 37ЊC for various periods (2, 4, 6, 24, 48, or 72 h). Reactions were stopped by the addition of 3 mL of acetonitrile, centrifuged (2000 × g, 5 min) and the supernatant was evaporated under nitrogen stream and reconstituted in 1 mL water. Additional aliquots of fecal slurry were spiked (in duplicate) with DON3Glc, DON, NIV3Glc, NIV, T2Glc, T-2, or HT-2 toxins and ACN was added immediately omitting incubation (time 0). All samples were then cleaned through C18 solid phase extraction columns (Agilent, Wokingham, UK) which were previously conditioned with 2 × 2 mL of methanol and 2 × 2 mL of water. Columns were washed twice with 2 mL of water and samples were eluted with 3 mL methanol into glass Pyrex tubes. The eluent was evaporated to dryness under nitrogen stream and reconstituted in 50% methanol for LC-MS/MS analysis. Masked zearalenone compounds (ZEN14Glc, ␣-ZEL14Glc, ␤-ZEL14Glc) and their respective free mycotoxins (ZEN, ␣-ZEL, ␤-ZEL) were studied individually in similar fecal batch culture experiments. Fresh fecal samples were used from donors 1 to 4 and 6 as donor 5 dropped out of the study due to antibiotic use. 
LC-MS/MS analysis
The liquid chromatography separation of the mycotoxin metabolites was performed on an Agilent 1200 HPLC system (Agilent Technologies, Wokingham, UK) with the metabolites separated on an Agilent Zorbax 5 m, 150 mm × 4.6 mm C18 column. Mobile phase solvents were (A) 0.1% aqueous acetic acid and (B) methanol for all experiments. The starting gradient was 30% B rising linearly to 100% B over 15 min, held at 100% B for 2 min then returned to 30% B and re-equilibrated for 8 min. The flow rate was 400 L/min and the injection volume was 20 L. The LC eluent was directed into, without splitting, a Q-Trap 4000 triple quadrupole mass spectrometer (AB Sciex, Warrington, UK) fitted with a TurboV Ion Spray TM (TIS) source. The mass spectrometer was run in both negative and positive ion mode with the following source settings: ion spray voltage -4000 V, temperature 200ЊC, Gases 1 & 2 set at 24 and 40 psi respectively and the Curtain Gas set at 10 psi in negative ion mode, for positive ions the conditions were the same, except for the spray voltage which was set at 4500 V. Ion transition parameters are summarized in Table 1 . Mycotoxins were quantified using the multiple reaction monitoring (MRM) technique. Standard solutions of 500 ng/mL were pumped directly into the TIS source via a syringe pump and their transition values optimized. Calibration curves were prepared for each metabolite by preparation of a series of standards ranging from 2 to 2000 pmoles/mL, no internal standard was used. The precursors used were (M+Ac)
− for all the zearalenone metabolites and (M+Na) + for T-2 and HT-2. Fecal extracts from hydrolysis experiments using masked zearalenone compounds were further analyzed for zearalenone metabolites by LC-HRMS (see online Supporting Material).
Statistical analysis
Time course experiments of microbial hydrolysis of masked mycotoxins were run on fecal samples from six donors in Figure 1 . Lack of hydrolysis of masked and free trichothecenes (DON3Glc, DON, NIV3Glc, NIV, T2Glc, T2, HT2, top panel) and zearalenone compounds (ZEN14Glc, ZEN, ␣-ZEL14Glc, ␣-ZEL, ␤-ZEL14Glc, ␤-ZEL, bottom panel) by artificial digestive juices of the upper gut containing digestive enzymes. All results are presented as average of triplicate incubations ± SD. T2 was partly converted to HT2 upon incubation with artificial digestive juices (13%) and enzyme-free controls (19%). All other mycotoxins were stable in enzyme-free control incubations (recovery DON3Glc 105.6 ± 7.6%, DON 103.1 ± 2.0%, NIV3Glc 102.3 ± 6.4%, NIV 105.9 ± 4.3%, T2Glc 116.0 ± 2.3%, HT2 116.0 ± 6.8, ZEN14Glc 104.1 ± 2.7%, ZEN 105.2 ± 1.1%, ␣-ZEL14Glc 106.9 ± 7.2%, ␣-ZEL 114.3 ± 1.6%, ␤-ZEL14Glc 107.4 ± 1.9%, ␤-ZEL 98.9 ± 11.1%).
total. The three trichothecene treatments were tested on samples from five donors. Four of these, plus one new donor, then provided, on a different occasion, another stool sample for testing the three zearalenone treatments. The results from the time course experiments were summarized by calculating the area under the curve (AUC) for each mycotoxin and each donor. To meet assumptions of normality and constant variance, AUC data were log-transformed. These were analyzed by mixed models, with random effects for donor and fecal sample nested within donor, and with mycotoxin treatment (6 treatments in total; 3 trichothecene treatments that were tested on the first fecal sample and 3 zearalenone treatments that were tested on the second fecal sample from each donor) as fixed effect. As the treatment effect was significant (p < 0.001), post hoc t-test was then performed to compare the treatment means. p < 0.05 was regarded statistically significant. Data were analyzed in Genstat 17th ed, Release 17.1 (VSN Int Ltd, Hemel Hempstead, UK). 
Results
Gastro-intestinal hydrolysis experiments showed that masked trichothecenes DON3Glc, NIV3Glc, and T2Glc were stable during incubations with artificial digestive juices (Fig. 1 top  panel) and enzyme-free controls with no evidence of hydrolysis or release of free DON, NIV, or T2. When incubating the free parent mycotoxins with artificial digestive juices, DON, NIV, and HT2 were also stable. T2 was partly converted to HT2 upon incubation with artificial digestive juices (13%) and enzyme-free controls (19%), indicating spontaneous conversion rather than enzymatic hydrolysis. Masked zearalenone compounds (ZEN14Glc, ␣-ZEL14Glc, ␤-ZEL14Glc) and parent mycotoxins (ZEN, ␣-ZEL, ␤-ZEL) were stable during incubations with artificial digestive juices ( Fig. 1 bottom panel) and enzyme-free controls indicating no hydrolysis in the upper GI-tract.
Epithelial absorption studies in Caco-2/TC7 cells revealed that masked trichothecenes (DON3Glc, NIV3Glc, and T2Glc) were not transported through epithelial monolayers with 91-102% of initial dose being recovered from the apical compartment and no detectable transport to the basolateral compartment (Fig. 2) . There was also no evidence of hydrolysis of the glucoside bond of any masked trichothecenes or any other metabolism by epithelial cells. Free DON on the other hand was transported efficiently through the epithelial cell layers with up to 38% of the added dose recovered from the basolateral compartment after 24 h of incubation whereas free NIV was transported more slowly (6% recovered from the basolateral compartment). Free T2 was spontaneously converted to HT2 in all cell cultures (both apically and basolaterally) as well as in cell-free controls. Both T2 and HT2 were efficiently transported through the epithelial cell layer with T2 reaching a basolateral maximum of 24% after 6 h and HT2 reaching a basolateral maximum of 32% of the added dose after 24 h.
The masked zearalenone compounds ZEN14Glc, ␣-ZEL14Glc, and ␤-ZEL14Glc were almost fully recovered from the apical compartment without evident hydrolysis or metabolism up to 24 h (Fig. 3) . For ZEN14Glc, ␣-ZEL14Glc, and ␤-ZEL14Glc, 91-93% of the starting amount were recovered after 24 h incubation. Only traces (up to 1% of dose) of ZEN14Glc and ␣-ZEL14Glc were recovered from the basolateral compartment after 6 and 24 h incubation. Free zearalenone compounds ZEN, ␣-ZEL, and ␤-ZEL were completely metabolized by epithelial cell monolayers after 24 h into undetected metabolites (Fig. 3) . Transport of the toxins to the basolateral compartments reached a maximum of 5.3 % of the dose for ZEN after 6 h, 1.6% for ␣-ZEL after 2 h and 9.4% for ␤-ZEL after 6 h of incubation. Only minor metabolites were detected in this study: ZEN was metabolized to 1% ␣-ZEL and 5% ␤-ZEL after 1 h of incubation, ␣-ZEL was metabolized to 2.5% ZEN and ␤-ZEL was metabolized to 2% ZEN after 1 h incubation. No other metabolites were detected at any time.
The hydrolysis and metabolism of masked mycotoxins by the human gut microbiota was assessed in freshly collected Results are presented as average of triplicate cultures ± SD. All mycotoxins were stable in cell-free DMEM culture medium after 24-h incubation (recovery DON3Glc 101.5 ± 0.6%, NIV3Glc 97.3 ± 1.3%, T2Glc 100.0 ± 9.4%, DON 102.4 ± 1.3%, NIV 103.6 ± 0.9%, T2/HT2 79.5 ± 1.1/15.1 ± 2.2%, HT2 98.6 ± 3.9).
fecal samples from five donors. Hydrolysis of DON3Glc was found to be a rapid process with hydrolysis (disappearance of DON3Glc and appearance of DON in culture medium) occurring between 2 and 6 h and complete hydrolysis being observed after 48 h for all five donors (Fig. 4, top panel) . NIV3Glc hydrolysis followed a very similar kinetics to DON3Glc (Fig. 4,  middle panel) . Hydrolysis of T2Glc by microbiota from five donors resulted in T2 appearing in culture medium followed by further de-acetylation to form HT2 (Fig. 4, bottom panel) . T2Glc hydrolysis started after 4 h, but was only completed in three out of five donor samples by 72 h. Hydrolysis to T2 only reached 30-50% of the total toxin added before further deacetylation to HT2 was observed.
Hydrolysis of masked zearalenone compounds by fecal microbiota of five donors occurred more rapidly as compared to trichothecenes with cleavage of ZEN14Glc, ␣-ZEL14Glc, and ␤-ZEL14Glc being detectable after 0.5 h of incubation and over 97% of all three masked compounds disappearing Results are presented as average of five donors ± SD. All mycotoxins were stable in bacteria-free M2 culture medium after 72-h incubation (recovery DON3Glc 96.8 ± 14.2%, NIV3Glc 97.1 ± 2.4%, T2Glc 103.8 ± 3.8%, DON 105.1 ± 3.9%, NIV 92.3 ± 11.2%, T2/HT2 94.3 ± 3.3/3.6 ± 1.6%, HT2 98.8 ± 13.3%).
after 4 h (Fig. 5 panels 1-3) . However, only 40% of the dose was recovered as free ZEN leaving up to 50% of ZEN14Glc to be metabolized to unidentified metabolites. Similarly, only 60% of ␣-ZEL14Glc and 30% of ␤-ZEL14Glc were recovered as free ␣-and ␤-ZEL, respectively and small amounts of ZEN (< 5%) leaving up to 40 or 70% of the dose to be unidentified. High resolution MS and accurate mass detection found zearalanol, zearalenol, zearalanone (ZAN), hydrolyzed zearalenone (HZEN) and decarboxylated hydrolyzed zearalenone (DHZEN) as potential zearalenone metabolites (see online Supporting Material).
Inter-individual differences in microbial hydrolysis rates of masked mycotoxins were explored by calculating the area under the curve (AUC) from each hydrolysis time course experiment for each donor (Fig. 6) . Hydrolysis of the two ␤-glucoside trichothecenes DON3Glc and NIV3Glc followed similar kinetics within the same donors. For both toxins, donor 1 showed the slowest hydrolysis rate (i.e. highest AUC) and donor 2 the fastest hydrolysis rate (i.e. lowest AUC). Hy- drolysis of T2Glc, a trichothecene ␣-glucoside, was significantly (p < 0.05) slower (higher AUC) for each individual donor compared to DON3Glc and NIV3Glc. Although experiments with zearalenone compounds and trichothecenes were performed with fecal samples from the same donors but collected on different days, this was accounted for in the statistical analysis. This showed that hydrolysis of masked zearalenone compounds was faster than trichothecenes resulting in significantly lower AUC (p < 0.05). No clear difference was observed between different zearalenone compounds for each individual donor.
Discussion
Evidence is mounting on the presence of masked mycotoxins in food and feed, but their toxicological assessment is still largely lacking. Upon ingestion of contaminated food, the major concern regarding masked mycotoxins is their potential hydrolytic breakdown and release into the gut lumen [13, 29] . Hence the current study aims to assess the fate of important masked trichothecenes (deoxynivalenol-3-glucoside DON3Glc, nivalenol-3-glucoside NIV3Glc,T-2-3-glucoside T2Glc) and masked zearalenone compounds (zearalenone-glucoside, ZEN14Glc; ␣-and ␤-zearalenol-glucoside, ␣-ZEL14Glc, and ␤ -ZEL14Glc) and their respective free parent mycotoxins under gastrointestinal conditions in vitro.
Hydrolysis of masked mycotoxins under gastro-intestinal conditions was assessed by exposing them to artificial saliva, artificial gastric and duodenal juices including all digestive enzymes and to artificial bile juice. None of the tested masked trichothecenes or zearalenone compounds were hydrolyzed under upper GI tract conditions. The results in the present study are in agreement with findings in the literature indicating that DON3Glc and T2Glc are stable under upper GI conditions in vitro [15, 18, 20] . Acetylated DON has also been found to be stable to digestive enzymes in vitro [30] . One in vivo study in rats confirms the stability of DON3Glc in the small intestine, but authors report hydrolysis of ZEN14Glc to free ZEN as early as the stomach [19] .
Following ingestion the transport of masked and free mycotoxins through the intestinal epithelium is defining the bioavailability and potential toxicity of mycotoxins in the gut. In the current study we used a 2 compartment Caco-2/TC7 cell model to assess epithelial absorption of modified and free mycotoxins in vitro. None of the tested masked mycotoxins were efficiently hydrolyzed or transported through the intestinal epithelial monolayers. Similarly, De Nijs et al. [20] reported no hydrolysis of DON3Glc by Caco-2 cells and very limited epithelial transport of DON3Glc (< 1% of dose transported to basolateral compartment) compared to DON (23% of dose transported) after 24 h. The authors concluded that the bioavailability of DON3Glc is much lower than DON [20] . This is in agreement with in vivo studies reporting the bioavailability (based on urinary excretion) of DON3Glc to be lower than DON in pigs within 24 h of oral exposure [31] and in rats within 48 h [32] . In the rat study, urinary excretion of DON metabolites was lower after an oral dose of DON3Glc compared to DON [32] , but fecal excretion of metabolites was similarly high in both treatments (approx. 65% of the DON3Glc and DON dose) [33] .
The fate of DON3Glc and DON in the rat may be different as sulfonates have been reported as major metabolites, which are not reported in pigs or humans. To our knowledge this is the first report assessing the transport of NIV3Glc and T2Glc in Caco-2 cells and the findings clearly indicate no absorption of intact mycotoxin-glucosides. This is in line with data on DON3Glc and suggests that glucose-bound trichothecenes are not bioavailable in the upper gut. Similarly, we found no evidence of substantial absorption of masked zearalenone compounds ZEN14Glc, ␣-ZEL14Glc, and ␤-ZEL14Glc in our transport model, indicating limited bioavailability of glucosebound zearalenone compounds. ZEN14Glc has recently been reported to be hydrolyzed and metabolized by the human breast cancer cell line MCF7, but authors used complete culture medium including fetal bovine serum and suggest that serum components rather than cells may have hydrolyzed the masked compound [34] . This notion is supported by our current study where we observe no hydrolysis of glucose-bound zearalenone compounds in cell cultures using serum-free culture medium.
Free mycotoxins on the other hand were efficiently transported through the gut epithelium in the current study. Our findings on free trichothecenes confirm literature reports showing DON and NIV absorption [20, 35, 36] , although NIV absorption in our study appears somewhat lower [37] . However, lower bioavailability of NIV compared to DON has been reported in broilers [38] and further studies will be required to elucidate possible differences in absorption and the potential role of efflux pumps. We found no evidence of metabolism of DON by intestinal cells, but deacetylation of acetylated DON by small intestinal preparations has been shown recently [30] . Our findings of the efficient transport of T2/HT2 demonstrate high bioavailability of these potent type-A trichothecenes.
Free zearalenone compounds ZEN, ␣-ZEL, and ␤-ZEL were very efficiently absorbed in the current transport study and also further metabolized by intestinal epithelial cells. Literature describes ␣-ZEL and ␤-ZEL as the major metabolites of ZEN produced by Caco-2 cells (41 and 32% of dose, respectively, [39, 40] ) which was not confirmed in our study. Further minor metabolites suggested in these studies include ZENglucuronide and to a lesser extent ␣-and ␤-ZEL-glucuronide, but these have not been determined in the current study. Similarly, ZEN and ␤-ZEL have been reported as major ␣-ZEL metabolites and ZEN and ␣-ZEL as major ␤-ZEL metabolites of Caco-2 cells by the same authors [39] , but again our findings did not confirm these results. Whether the differences in metabolic capability or expression of active transporters of different Caco-2 clones used in the two studies can be responsible for this discrepancy remains to be determined.
The findings of the current study on complete hydrolysis of DON3Glc by human fecal microbiota after 24 h confirms published reports [18, 24] . NIV3Glc, also a type B ␤-glucoside trichothecene, was hydrolyzed in a very similar way to DON3Glc in all individuals and recovered as free parent mycotoxin NIV. Given the time scale of large intestinal transit in humans both DON3Glc and NIV3Glc are likely to be bioavailable as free DON and NIV in the human large intestine and contribute to overall toxic burden. T2Glc, a type A ␣-glucoside, showed distinctly different kinetics with slower hydrolysis by gut microbiota of each individual donor in this study compared to DON3Glc and NIV3Glc. Contradictory to the literature [15] we have recovered all hydrolyzed T2Glc as free T2&HT2 toxin, but due to the slower kinetics of release the bioavailability of T2Glc and contribution to toxicity in humans may be limited.
Masked zearalenone compounds were hydrolyzed more rapidly by gut microbiota of all donors compared to the trichothecene-glucosides and no differences were observed between individual donors for each compound. Hydrolysis of ZEN14Glc, ␣-ZEL14Glc and ␤-ZEL14Glc resulted in rapid release of 30-60% of the dose as free parent mycotoxins which will be bioavailable in the human large intestine and contribute to toxicity. The fate of the remaining 40-70% of ZEN compounds is as yet unknown. This is in agreement with the findings of Dall' Erta and colleagues [18] who reported an apparent loss (mass balance) of 40-60% of ZEN14Glc after 24 h of incubation. They reported the release of free ZEN and mention 10 other unidentified catabolic products. It is not known if the 'lost' compounds were bound or adsorbed to the cell material as this was separated from the extracts before analysis. In the present study we propose zearalanol, zearalenol, zearalanone (ZAN), hydrolyzed zearalenone (HZEN), and decarboxylated hydrolyzed zearalenone (DHZEN) as (9 of 10) 1600680 potential metabolites using HRMS and accurate mass detection. HZEN and DHZEN have been identified recently [41] and described as anaerobic microbial ZEN degradation products in a study comparing several microbial feed additives [42] . Other microbial additives tested produced a range of unidentified metabolites under both aerobic and anaerobic conditions.
Conclusion
This study aimed to predict bioavailability of six major masked mycotoxins, namely DON3Glc, NIV3Glc, T2Glc, ZEN14Glc, ␣-ZEL14Glc, and ␤-ZEL14Glc, in the human gut using in vitro studies. We found that all masked mycotoxins were stable toward gastro-intestinal digestive juices and were not efficiently transported through intestinal epithelial cell monolayers. However, upon contact with human gut microbiota, all masked mycotoxins were hydrolyzed efficiently. DON3Glc and NIV3Glc are likely to contribute to overall toxicity as free DON and NIV, whereas microbial hydrolysis of T2Glc may be too slow to increase its bioavailability in vivo. Colonic bioavailability of masked ZEN compounds is high as they are rapidly hydrolyzed by gut microbiota, and the released zearalenone compounds are highly reactive with gut microbiota and epithelial cells. Future in vivo studies will be required to describe the contribution of colonic hydrolysis of masked mycotoxins to their absorption and toxicity in the body. 
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